|
1
|
Cooper TA, Wan L and Dreyfuss G: RNA and
disease. Cell. 136:777–793. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Brosnan CA and Voinnet O: The long and the
short of noncoding RNAs. Curr Opin Cell Biol. 21:416–425.
2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Derrien T, Johnson R, Bussotti G, Tanzer
A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG,
et al: The GENCODE v7 catalog of human long noncoding RNAs:
Analysis of their gene structure, evolution, and expression. Genome
Res. 22:1775–1789. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ma L, Bajic VB and Zhang Z: On the
classification of long non-coding RNAs. RNA Biology. 10:924–933.
2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yao RW, Wang Y and Chen LL: Cellular
functions of long noncoding RNAs. Nat Cell Biol. 21:542–551.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fang S, Zhang L, Guo J, Niu Y, Wu Y, Li H,
Zhao L, Li X, Teng X, Sun X, et al: NONCODEV5: A comprehensive
annotation database for long non-coding RNAs. Nucleic Acids Res.
46(D1):D308–D314. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mattick JS, Amaral PP, Carninci P,
Carpenter S, Chang HY, Chen LL, Chen R, Dean C, Dinger ME,
Fitzgerald KA, et al: Long non-coding RNAs: Definitions, functions,
challenges and recommendations. Nat Rev Mol Cell Biol. 24:430–447.
2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Loewer S, Cabili MN, Guttman M, Loh YH,
Thomas K, Park IH, Garber M, Curran M, Onder T, Agarwal S, et al:
Large intergenic non-coding RNA-RoR modulates reprogramming of
human induced pluripotent stem cells. Nat Genet. 42:1113–1117.
2010.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Takahashi K, Yan IK, Haga H and Patel T:
Modulation of hypoxia-signaling pathways by extracellular linc-RoR.
J Cell Sci. 127 (Pt 7):1585–1594. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yang G, Lu X and Yuan L: LncRNA: A link
between RNA and cancer. Biochim Biophys Acta. 1839:1097–1109.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yao ZT, Yang YM, Sun MM, He Y, Liao L,
Chen KS and Li B: New insights into the interplay between long
non-coding RNAs and RNA-binding proteins in cancer. Cancer Commun
(Lond). 42:117–140. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wapinski O and Chang HY: Long noncoding
RNAs and human disease. Trends Cell Biol. 21:354–361.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sun X and Malhotra A: Noncoding RNAs
(ncRNA) in hepato cancer: A review. J Environ Pathol Toxicol Oncol.
37:15–25. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Huang Z, Zhou JK, Peng Y, He W and Huang
C: The role of long noncoding RNAs in hepatocellular carcinoma. Mol
Cancer. 19(77)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xie H, Ma H and Zhou D: Plasma HULC as a
promising novel biomarker for the detection of hepatocellular
carcinoma. Biomed Res Int. 2013(136106)2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pan YF, Qin T, Feng L and Yu ZJ:
Expression profile of altered long non-coding RNAs in patients with
HBV-associated hepatocellular carcinoma. J Huazhong Univ Sci
Technolog Med Sci. 33:96–101. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hentze MW, Castello A, Schwarzl T and
Preiss T: A brave new world of RNA-binding proteins. Nat Rev Mol
Cell Biol. 19:327–341. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gerstberger S, Hafner M and Tuschl T: A
census of human RNA-binding proteins. Nat Rev Genet. 15:829–845.
2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tang Q and Hann SS: HOTAIR: An oncogenic
long non-coding RNA in human cancer. Cell Physiol Biochem.
47:893–913. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gebauer F, Schwarzl T, Valcárcel J and
Hentze MW: RNA-binding proteins in human genetic disease. Nat Rev
Genet. 22:185–198. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Corley M, Burns MC and Yeo GW: How
RNA-Binding proteins interact with RNA: Molecules and mechanisms.
Mol Cell. 78:9–29. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mohibi S, Chen X and Zhang J: Cancer
the'RBP'eutics-RNA-binding proteins as therapeutic targets for
cancer. Pharmacol Ther. 203(107390)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pereira B, Billaud M and Almeida R:
RNA-Binding proteins in cancer: Old players and new actors. Trends
Cancer. 3:506–528. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sun M, Gadad SS, Kim DS and Kraus WL:
Discovery, annotation, and functional analysis of long noncoding
RNAs controlling cell-cycle gene expression and proliferation in
breast cancer cells. Mol Cell. 59:698–711. 2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Morris KV and Mattick JS: The rise of
regulatory RNA. Nat Rev Genet. 15:423–437. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Takahashi K, Yan I, Haga H and Patel T:
Long noncoding RNA in liver diseases. Hepatology. 60:744–753.
2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yang M, Lu H, Liu J, Wu S, Kim P and Zhou
X: lncRNAfunc: A knowledgebase of lncRNA function in human cancer.
Nucleic Acids Res. 50(D1):D1295–D1306. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ferre F, Colantoni A and Helmer-Citterich
M: Revealing protein-lncRNA interaction. Brief Bioinform.
17:106–116. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jonas K, Calin GA and Pichler M:
RNA-Binding proteins as important regulators of long non-coding
RNAs in cancer. Int J Mol Sci. 21(2969)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Xia A, Yuan W, Wang Q, Xu J, Gu Y, Zhang
L, Chen C, Wang Z, Wu D, He Q, et al: The cancer-testis lncRNA
lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K
and activating YAP1 transcription. Nat Cancer. 3:203–218.
2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Huarte M, Guttman M, Feldser D, Garber M,
Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M,
et al: A large intergenic noncoding RNA induced by p53 mediates
global gene repression in the p53 response. Cell. 142:409–419.
2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yan C, Chen J and Chen N: Long noncoding
RNA MALAT1 promotes hepatic steatosis and insulin resistance by
increasing nuclear SREBP-1c protein stability. Sci Rep.
6(22640)2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Huang PS, Lin YH, Chi HC, Tseng YH, Chen
CY, Lin TK, Yeh CT and Lin KH: Dysregulated FAM215A Stimulates
LAMP2 expression to confer drug-resistant and malignant in human
liver cancer. Cells. 9(961)2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sondergaard JN, Sommerauer C, Atanasoai I,
Hinte LC, Geng K, Guiducci G, Bräutigam L, Aouadi M, Stojic L,
Barragan I and Kutter C: CCT3-LINC00326 axis regulates
hepatocarcinogenic lipid metabolism. Gut. 71:2081–2092.
2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Li Y, Chen X, Huang H, Liao L, Chong H, Li
G, Yuan T, Lu W, Deng S and Huang Q: A feedback loop between
NONHSAT024276 and PTBP1 inhibits tumor progression and glycolysis
in HCC by increasing the PKM1/PKM2 ratio. Cancer Sci.
114:1519–1540. 2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Xu M, Zhao X, Zhao S, Yang Z, Yuan W, Han
H, Zhang B, Zhou L, Zheng S and Li MD: Landscape analysis of
lncRNAs shows that DDX11-AS1 promotes cell-cycle progression in
liver cancer through the PARP1/p53 axis. Cancer Lett. 520:282–294.
2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wang H, Ma P, Liu P, Guo D, Liu Z and
Zhang Z: lncRNA SNHG6 promotes hepatocellular carcinoma progression
by interacting with HNRNPL/PTBP1 to facilitate SETD7/LZTFL1 mRNA
destabilization. Cancer Lett. 520:121–131. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jiang W, Ou ZL, Zhu Q, Yao YB and Zai HY:
LncRNA OIP5-AS1 aggravates the stemness of hepatoblastoma through
recruiting PTBP1 to increase the stability of beta-catenin. Pathol
Res Pract. 232(153829)2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hammerle M, Gutschner T, Uckelmann H,
Ozgur S, Fiskin E, Gross M, Skawran B, Geffers R, Longerich T,
Breuhahn K, et al: Posttranscriptional destabilization of the
liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding
protein 1 (IGF2BP1). Hepatology. 58:1703–1712. 2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Peng SS, Chen CY, Xu N and Shyu AB: RNA
stabilization by the AU-rich element binding protein, HuR, an ELAV
protein. EMBO J. 17:3461–3470. 1998.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Priyanka P, Sharma M, Das S and Saxena S:
The lncRNA HMS recruits RNA-binding protein HuR to stabilize the
3'-UTR of HOXC10 mRNA. J Biol Chem. 297(100997)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cao C, Sun J, Zhang D, Guo X, Xie L, Li X,
Wu D and Liu L: The long intergenic noncoding RNA UFC1, a target of
MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to
increase levels of β-catenin in HCC cells. Gastroenterology.
148:415–426 e18. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Tu ZQ, Li RJ, Mei JZ and Li XH:
Down-regulation of long non-coding RNA GAS5 is associated with the
prognosis of hepatocellular carcinoma. Int J Clin Exp Pathol.
7:4303–4309. 2014.PubMed/NCBI
|
|
45
|
Hu G, Lou Z and Gupta M: The long
non-coding RNA GAS5 cooperates with the eukaryotic translation
initiation factor 4E to regulate c-Myc translation. PLoS One.
9(e107016)2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y,
Yang X, Shen J, Liu Q and Zhang J: Long noncoding RNA GAS5
suppresses the migration and invasion of hepatocellular carcinoma
cells via miR-21. Tumour Biol. 37:2691–2702. 2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhao P, Cui X, Zhao L, Liu L and Wang D:
Overexpression of growth-arrest-specific transcript 5 improved
cisplatin sensitivity in hepatocellular carcinoma through sponging
miR-222. DNA Cell Biol. 39:724–732. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Fang P, Xiang L, Chen W, Li S, Huang S, Li
J, Zhuge L, Jin L, Feng W, Chen Y and Pan C: LncRNA GAS5 enhanced
the killing effect of NK cell on liver cancer through regulating
miR-544/RUNX3. Innate Immun. 25:99–109. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Lin G, Wu T, Gao X, He Z and Nong W:
Research progress of long non-coding RNA GAS5 in malignant tumors.
Front Oncol. 12(846497)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Shihabudeen Haider Ali MS, Cheng X, Moran
M, Haemmig S, Naldrett MJ, Alvarez S, Feinberg MW and Sun X: LncRNA
Meg3 protects endothelial function by regulating the DNA damage
response. Nucleic Acids Res. 47:1505–1522. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Wu J, Pang R, Li M, Chen B, Huang J and
Zhu Y: m6A-Induced LncRNA MEG3 suppresses the proliferation,
migration and invasion of hepatocellular carcinoma cell through
miR-544b/BTG2 signaling. Onco Targets Ther. 14:3745–3755.
2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhang L, Yang F, Yuan JH, Yuan SX, Zhou
WP, Huo XS, Xu D, Bi HS, Wang F and Sun SH: Epigenetic activation
of the MiR-200 family contributes to H19-mediated metastasis
suppression in hepatocellular carcinoma. Carcinogenesis.
34:577–586. 2013.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Lee TI and Young RA: Transcriptional
regulation and its misregulation in disease. Cell. 152:1237–1251.
2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Bridges MC, Daulagala AC and Kourtidis A:
LNCcation: LncRNA localization and function. J Cell Biol.
220(e202009045)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Pintacuda G, Wei G, Roustan C, Kirmizitas
BA, Solcan N, Cerase A, Castello A, Mohammed S, Moindrot B,
Nesterova TB and Brockdorff N: hnRNPK recruits PCGF3/5-PRC1 to the
Xist RNA B-Repeat to establish polycomb-mediated chromosomal
silencing. Mol Cell. 68:955–969.e10. 2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Wang Y, Zhu P, Luo J, Wang J, Liu Z, Wu W,
Du Y, Ye B, Wang D, He L, et al: LncRNA HAND2-AS1 promotes liver
cancer stem cell self-renewal via BMP signaling. EMBO J.
38(e101110)2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Genander M, Cook PJ, Ramsköld D, Keyes BE,
Mertz AF, Sandberg R and Fuchs E: BMP signaling and its pSMAD1/5
target genes differentially regulate hair follicle stem cell
lineages. Cell Stem Cell. 15:619–633. 2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Kirmizitas A, Meiklejohn S, Ciau-Uitz A,
Stephenson R and Patient R: Dissecting BMP signaling input into the
gene regulatory networks driving specification of the blood stem
cell lineage. Proc Natl Acad Sci USA. 114:5814–5821.
2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Andersen P, Tampakakis E, Jimenez DV,
Kannan S, Miyamoto M, Shin HK, Saberi A, Murphy S, Sulistio E,
Chelko SP and Kwon C: Precardiac organoids form two heart fields
via Bmp/Wnt signaling. Nat Commun. 9(3140)2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Xu W, Wu Y, Fang X, Zhang Y, Cai N, Wen J,
Liao J, Zhang B, Chen X and Chu L: SnoRD126 promotes the
proliferation of hepatocellular carcinoma cells through
transcriptional regulation of FGFR2 activation in combination with
hnRNPK. Aging (Albany NY). 13:13300–13317. 2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Castellanos-Rubio A, Fernandez-Jimenez N,
Kratchmarov R, Luo X, Bhagat G, Green PH, Schneider R, Kiledjian M,
Bilbao JR and Ghosh S: A long noncoding RNA associated with
susceptibility to celiac disease. Science. 352:91–95.
2016.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Li H, An J, Wu M, Zheng Q, Gui X, Li T, Pu
H and Lu D: LncRNA HOTAIR promotes human liver cancer stem cell
malignant growth through downregulation of SETD2. Oncotarget.
6:27847–27864. 2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Wu M, Lin Z, Li X, Xin X, An J, Zheng Q,
Yang Y and Lu D: HULC cooperates with MALAT1 to aggravate liver
cancer stem cells growth through telomere repeat-binding factor 2.
Sci Rep. 6(36045)2016.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Gao J, Dai C, Yu X, Yin XB and Zhou F:
Long noncoding RNA LINC00324 exerts protumorigenic effects on liver
cancer stem cells by upregulating fas ligand via PU box binding
protein. FASEB J. 34:5800–5817. 2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Wu J, Zhu P, Lu T, Du Y, Wang Y, He L, Ye
B, Liu B, Yang L, Wang J, et al: The long non-coding RNA LncHDAC2
drives the self-renewal of liver cancer stem cells via activation
of Hedgehog signaling. J Hepatol. 70:918–929. 2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Quagliata L, Matter MS, Piscuoglio S,
Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z,
Boldanova T, et al: Long noncoding RNA HOTTIP/HOXA13 expression is
associated with disease progression and predicts outcome in
hepatocellular carcinoma patients. Hepatology. 59:911–923.
2014.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Rong Z, Wang Z, Wang X, Qin C and Geng W:
Molecular interplay between linc01134 and YY1 dictates
hepatocellular carcinoma progression. J Exp Clin Cancer Res.
39(61)2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Li Y, Zhuang W, Huang M and Li X: Long
noncoding RNA DDX11-AS1 epigenetically represses LATS2 by
interacting with EZH2 and DNMT1 in hepatocellular carcinoma.
Biochem Biophys Res Commun. 514:1051–1057. 2019.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Yang S, Ruan X, Hu B, Tu J and Cai H:
lncRNA SNHG9 enhances liver cancer stem cell self-renewal and
tumorigenicity by negatively regulating PTEN expression via
recruiting EZH2. Cell Tissue Res. 394:441–453. 2023.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Cusenza VY, Tameni A, Neri A and Frazzi R:
The lncRNA epigenetics: The significance of m6A and m5C lncRNA
modifications in cancer. Front Oncol. 13(1063636)2023.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Pan XY, Huang C and Li J: The emerging
roles of m(6)A modification in liver carcinogenesis. Int J Biol
Sci. 17:271–284. 2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Chen YT, Xiang D, Zhao XY and Chu XY:
Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by
m(6)A methylation promotes disease progression and sorafenib
resistance. Hum Cell. 34:1800–1811. 2021.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Peng L, Pan B, Zhang X, Wang Z, Qiu J,
Wang X and Tang N: Lipopolysaccharide facilitates immune escape of
hepatocellular carcinoma cells via m6A modification of lncRNA
MIR155HG to upregulate PD-L1 expression. Cell Biol Toxicol.
38:1159–1173. 2022.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Liu J, Zhang N, Zeng J, Wang T, Shen Y, Ma
C and Yang M: N(6) -methyladenosine-modified lncRNA ARHGAP5-AS1
stabilises CSDE1 and coordinates oncogenic RNA regulons in
hepatocellular carcinoma. Clin Transl Med. 12(e1107)2022.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Sun Z, Xue S, Zhang M, Xu H, Hu X, Chen S,
Liu Y, Guo M and Cui H: Aberrant NSUN2-mediated m(5)C modification
of H19 lncRNA is associated with poor differentiation of
hepatocellular carcinoma. Oncogene. 39:6906–6919. 2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Schultz CW, Preet R, Dhir T, Dixon DA and
Brody JR: Understanding and targeting the disease-related RNA
binding protein human antigen R (HuR). Wiley Interdiscip Rev RNA.
11(e1581)2020.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Wang J, Wang H, Zhang Y, Zhen N, Zhang L,
Qiao Y, Weng W, Liu X, Ma L, Xiao W, et al: Mutual inhibition
between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced
tumourigenesis in liver cancer. Cell Signal. 26:1048–1059.
2014.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Li H, Li J, Jia S, Wu M, An J, Zheng Q,
Zhang W and Lu D: miR675 upregulates long noncoding RNA H19 through
activating EGR1 in human liver cancer. Oncotarget. 6:31958–31984.
2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Gao JZ, Li J, Du JL and Li XL: Long
non-coding RNA HOTAIR is a marker for hepatocellular carcinoma
progression and tumor recurrence. Oncol Lett. 11:1791–1798.
2016.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Yu M, Qian K, Wang G, Xiao Y, Zhu Y and Ju
L: Histone methyltransferase SETD2: An epigenetic driver in clear
cell renal cell carcinoma. Front Oncol. 13(1114461)2023.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Gao J, Dai C, Yu X, Yin XB and Zhou F:
LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay
hepatocellular carcinoma development by impairing CEBPB-interaction
with CDCA7. Cell Cycle. 19:870–883. 2020.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Cai Y, Lyu T, Li H, Liu C, Xie K, Xu L, Li
W, Liu H, Zhu J, Lyu Y, et al: LncRNA CEBPA-DT promotes liver
cancer metastasis through DDR2/beta-catenin activation via
interacting with hnRNPC. J Exp Clin Cancer Res.
41(335)2022.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Nguyen TM, Kabotyanski EB, Reineke LC,
Shao J, Xiong F, Lee JH, Dubrulle J, Johnson H, Stossi F, Tsoi PS,
et al: The SINEB1 element in the long non-coding RNA Malat1 is
necessary for TDP-43 proteostasis. Nucleic Acids Res. 48:2621–2642.
2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Zhang Y, Xu Y, Feng L, Li F, Sun Z, Wu T,
Shi X, Li J and Li X: Comprehensive characterization of lncRNA-mRNA
related ceRNA network across 12 major cancers. Oncotarget.
7:64148–64167. 2016.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Li X, Wang X, Cheng Z and Zhu Q: AGO2 and
its partners: A silencing complex, a chromatin modulator, and new
features. Crit Rev Biochem Mol Biol. 55:33–53. 2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Feng J, Yang G, Liu Y, Gao Y, Zhao M, Bu
Y, Yuan H, Yuan Y, Yun H, Sun M, et al: LncRNA PCNAP1 modulates
hepatitis B virus replication and enhances tumor growth of liver
cancer. Theranostics. 9:5227–5245. 2019.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Wang H, Huo X, Yang XR, He J, Cheng L,
Wang N, Deng X, Jin H, Wang N, Wang C, et al: STAT3-mediated
upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer
metastasis by regulating SOX4. Mol Cancer. 16(136)2017.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Zhang Y and Zhou H: LncRNA BCAR4 promotes
liver cancer progression by upregulating ANAPC11 expression through
sponging miR-1261. Int J Mol Med. 46:159–166. 2020.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Hou Z, Xu X, Zhou L, Fu X, Tao S, Zhou J,
Tan D and Liu S: The long non-coding RNA MALAT1 promotes the
migration and invasion of hepatocellular carcinoma by sponging
miR-204 and releasing SIRT1. Tumour Biol.
39(1010428317718135)2017.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Wang LP, Wang JP and Wang XP: HOTAIR
contributes to the growth of liver cancer via targeting miR-217.
Oncol Lett. 15:7963–7972. 2018.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Liu J, Li W, Zhang J, Ma Z, Wu X and Tang
L: Identification of key genes and long non-coding RNA associated
ceRNA networks in hepatocellular carcinoma. PeerJ.
7(e8021)2019.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong
F, Ren D, Ye X, Li C, Wang Y, et al: Circular RNAs function as
ceRNAs to regulate and control human cancer progression. Mol
Cancer. 17(79)2018.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Liu CX and Chen LL: Circular RNAs:
Characterization, cellular roles, and applications. Cell.
185:2016–2034. 2022.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Shen H, Liu B, Xu J, Zhang B, Wang Y, Shi
L and Cai X: Circular RNAs: Characteristics, biogenesis, mechanisms
and functions in liver cancer. J Hematol Oncol.
14(134)2021.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Louis C, Leclerc D and Coulouarn C:
Emerging roles of circular RNAs in liver cancer. JHEP Rep.
4(100413)2022.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Liu H, Lan T, Li H, Xu L, Chen X, Liao H,
Chen X, Du J, Cai Y, Wang J, et al: Circular RNA circDLC1 inhibits
MMP1-mediated liver cancer progression via interaction with HuR.
Theranostics. 11:1396–1411. 2021.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Meng H, Niu R, Huang C and Li J: Circular
RNA as a novel biomarker and therapeutic target for HCC. Cells.
11(1948)2022.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Zhou RJ and Lv HZ: Knockdown of ACTA2-AS1
promotes liver cancer cell proliferation, migration and invasion.
Mol Med Rep. 19:2263–2270. 2019.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Jiao Y, Li Y, Jia B, Chen Q, Pan G, Hua F
and Liu Y: The prognostic value of lncRNA SNHG4 and its potential
mechanism in liver cancer. Biosci Rep.
40(BSR20190729)2020.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Ding C, Cheng S, Yang Z, Lv Z, Xiao H, Du
C, Peng C, Xie H, Zhou L, Wu J and Zheng S: Long non-coding RNA
HOTAIR promotes cell migration and invasion via down-regulation of
RNA binding motif protein 38 in hepatocellular carcinoma cells. Int
J Mol Sci. 15:4060–4076. 2014.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Conigliaro A, Costa V, Lo Dico A, Saieva
L, Buccheri S, Dieli F, Manno M, Raccosta S, Mancone C, Tripodi M,
et al: CD90+ liver cancer cells modulate endothelial cell phenotype
through the release of exosomes containing H19 lncRNA. Mol Cancer.
14(155)2015.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Guo Y, Bai M, Lin L, Huang J, An Y, Liang
L, Liu Y and Huang W: LncRNA DLEU2 aggravates the progression of
hepatocellular carcinoma through binding to EZH2. Biomed
Pharmacother. 118(109272)2019.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Pan S and Chen R: Pathological implication
of protein post-translational modifications in cancer. Mol Aspects
Med. 86(101097)2022.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Sharma B, Prabhakaran V, Desai A, Bajpai
J, Verma R and Swain P: Post-translational modifications (PTMs),
from a cancer perspective: An overview. Oncogen. 2(12)2019.
|
|
105
|
Zhang X, Wang W, Zhu W, Dong J, Cheng Y,
Yin Z and Shen F: Mechanisms and functions of long non-coding RNAs
at multiple regulatory levels. Int J Mol Sci.
20(5573)2019.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Toraih EA, Ellawindy A, Fala SY, Al Ageeli
E, Gouda NS, Fawzy MS and Hosny S: Oncogenic long noncoding RNA
MALAT1 and HCV-related hepatocellular carcinoma. Biomed
Pharmacother. 102:653–669. 2018.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Chen R, Liu Y, Zhuang H, Yang B, Hei K,
Xiao M, Hou C, Gao H, Zhang X, Jia C, et al: Quantitative
proteomics reveals that long non-coding RNA MALAT1 interacts with
DBC1 to regulate p53 acetylation. Nucleic Acids Res. 45:9947–9959.
2017.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Luo ML, Li J, Shen L, Chu J, Guo Q, Liang
G, Wu W, Chen J, Chen R and Song E: The role of APAL/ST8SIA6-AS1
lncRNA in PLK1 activation and mitotic catastrophe of tumor cells. J
Natl Cancer Inst. 112:356–368. 2020.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y,
Yan F, Zhu P, Wu J, Huang G, et al: Mesenchymal Stem Cells Promote
Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and
miR-34a. Cancer Res. 77:6704–6716. 2017.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Li B, Xiong X, Xu J, Peng D, Nie G, Wen N,
Wang Y and Lu J: METTL3-mediated m(6)A modification of lncRNA
TSPAN12 promotes metastasis of hepatocellular carcinoma through
SENP1-depentent deSUMOylation of EIF3I. Oncogene. 43:1050–1062.
2024.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao
Y, Xu W, Niu Y, Cheng L, Maity SN, et al: LncRNA-p21 alters the
antiandrogen enzalutamide-induced prostate cancer neuroendocrine
differentiation via modulating the EZH2/STAT3 signaling. Nat
Commun. 10(2571)2019.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou
A, Liu J, Che L and Li J: Long noncoding RNA GAS5 inhibits
progression of colorectal cancer by interacting with and triggering
YAP phosphorylation and degradation and is negatively regulated by
the m(6)A reader YTHDF3. Mol Cancer. 18(143)2019.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Yoon JH, Abdelmohsen K, Kim J, Yang X,
Martindale JL, Tominaga-Yamanaka K, White EJ, Orjalo AV, Rinn JL,
Kreft SG, et al: Scaffold function of long non-coding RNA HOTAIR in
protein ubiquitination. Nat Commun. 4(2939)2013.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Li Z, Liu L, Feng C, Qin Y, Xiao J, Zhang
Z and Ma L: LncBook 2.0: Integrating human long non-coding RNAs
with multi-omics annotations. Nucleic Acids Res. 51(D1):D186–D191.
2023.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Van Nostrand EL, Freese P, Pratt GA, Wang
X, Wei X, Xiao R, Blue SM, Chen JY, Cody NAL, Dominguez D, et al: A
large-scale binding and functional map of human RNA-binding
proteins. Nature. 583:711–719. 2020.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Yang YC, Di C, Hu B, Zhou M, Liu Y, Song
N, Li Y, Umetsu J and Lu ZJ: CLIPdb: A CLIP-seq database for
protein-RNA interactions. BMC Genomics. 16(51)2015.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Gao Y, Shang S, Guo S, Li X, Zhou H, Liu
H, Sun Y, Wang J, Wang P, Zhi H, et al: Lnc2Cancer 3.0: An updated
resource for experimentally supported lncRNA/circRNA cancer
associations and web tools based on RNA-seq and scRNA-seq data.
Nucleic Acids Res. 49(D1):D1251–D1258. 2021.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Yi Y, Zhao Y, Huang Y and Wang D: A Brief
Review of RNA-Protein interaction database resources. Noncoding
RNA. 3(6)2017.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Hafner M, Katsantoni M, Köster T, Marks J,
Mukherjee J, Staiger D, Ule J and Zavolan M: CLIP and complementary
methods. Nat Rev Methods Primers. 1(20)2021.
|
|
120
|
Torres M, Becquet D, Guillen S, Boyer B,
Moreno M, Blanchard MP, Franc JL and François-Bellan AM: RNA
pull-down procedure to identify RNA targets of a long Non-coding
RNA. J Vis Exp. 57379:2018.PubMed/NCBI View
Article : Google Scholar
|
|
121
|
Chu C, Quinn J and Chang HY: Chromatin
isolation by RNA purification (ChIRP). J Vis Exp.
61(3912)2012.PubMed/NCBI View
Article : Google Scholar
|
|
122
|
Engreitz J, Lander ES and Guttman M: RNA
antisense purification (RAP) for mapping RNA interactions with
chromatin. Methods Mol Biol. 1262:183–197. 2015.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Liu ZP: Predicting lncRNA-protein
interactions by machine learning methods: A review. Curr Bioinf.
15:831–840. 2020.
|
|
124
|
Lu K, Fan Q and Zou X: Antisense
oligonucleotide is a promising intervention for liver diseases.
Front Pharmacol. 13(1061842)2022.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Cremer J, Elston R, Campbell FM, Kendrick
S, Paff M, Quinn G and Theodore D: B-Clear phase 2b study design:
Establishing the efficacy and safety of bepirovirsen in patients
with chronic hepatitis B virus infection. Adv Ther. 40:4101–4110.
2023.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Klec C, Gutschner T, Panzitt K and Pichler
M: Involvement of long non-coding RNA HULC (highly up-regulated in
liver cancer) in pathogenesis and implications for therapeutic
intervention. Expert Opin Ther Targets. 23:177–186. 2019.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Tian NN, Zheng YB, Li ZP, Zhang FW and
Zhang JF: Histone methylatic modification mediates the
tumor-suppressive activity of curcumol in hepatocellular carcinoma
via an Hotair/EZH2 regulatory axis. J Ethnopharmacol.
280(114413)2021.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Amodio N, Raimondi L, Juli G, Stamato MA,
Caracciolo D, Tagliaferri P and Tassone P: MALAT1: A druggable long
non-coding RNA for targeted anti-cancer approaches. J Hematol
Oncol. 11(63)2018.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Shen W, De Hoyos CL, Migawa MT, Vickers
TA, Sun H, Low A, Bell TA III, Rahdar M, Mukhopadhyay S, Hart CE,
et al: Chemical modification of PS-ASO therapeutics reduces
cellular protein-binding and improves the therapeutic index. Nat
Biotechnol. 37:640–650. 2019.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Debacker AJ, Voutila J, Catley M, Blakey D
and Habib N: Delivery of oligonucleotides to the liver with GalNAc:
From research to registered therapeutic drug. Mol Ther.
28:1759–1771. 2020.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Smekalova EM, Kotelevtsev YV, Leboeuf D,
Shcherbinina EY, Fefilova AS, Zatsepin TS and Koteliansky V: lncRNA
in the liver: Prospects for fundamental research and therapy by RNA
interference. Biochimie. 131:159–172. 2016.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan
T, Yang W, Tian C, Miao Z, Wang T and Yang S: Small molecules in
targeted cancer therapy: Advances, challenges, and future
perspectives. Signal Transduct Target Ther. 6(201)2021.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Suravajhala R, Gupta S, Kumar N and
Suravajhala P: Deciphering LncRNA-protein interactions using
docking complexes. J Biomol Struct Dyn. 40:3769–3776.
2022.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Zhang N and Wen K: The role of lncRNA
binding to RNA-binding proteins to regulate mRNA stability in
cancer progression and drug resistance mechanisms (Review). Oncol
Rep. 52(142)2024.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Zhu J, Mo YY and Peng WX: RNA binding
protein-mediated competing endogenous RNA mechanism in cancer.
Gene. 963(149606)2025.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Wang H, Guo R, Du Z, Bai L, Li L, Cui J,
Li W, Hoffman AR and Hu JF: Epigenetic targeting of granulin in
hepatoma cells by synthetic CRISPR dCas9 Epi-suppressors. Mol Ther
Nucleic Acids. 11:23–33. 2018.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Ali HS, Boshra MS, El Meteini MS, Shafei
AE and Matboli M: lncRNA-RP11-156p1.3, novel diagnostic and
therapeutic targeting via CRISPR/Cas9 editing in hepatocellular
carcinoma. Genomics. 112:3306–3314. 2020.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Ye S and Ni Y: lncRNA SNHG9 promotes cell
proliferation, migration, and invasion in human hepatocellular
carcinoma cells by increasing GSTP1 methylation, as revealed by
CRISPR-dCas9. Front Mol Biosci. 8(649976)2021.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Tong LW, Hu YS, Yu SJ, Li CL and Shao JW:
Current application and future perspective of CRISPR/cas9 gene
editing system mediated immune checkpoint for liver cancer
treatment. Nanotechnology. 35:2024.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Paunovska K, Loughrey D and Dahlman JE:
Drug delivery systems for RNA therapeutics. Nat Rev Genet.
23:265–280. 2022.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Sioud M: How the initial discovery of
modified RNA enabled evasion of innate immune responses and
facilitated the development of RNA therapeutics. Scand J Immunol.
98(e13282)2023.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Eun JW, Cheong JY, Jeong JY and Kim HS: A
new understanding of long non-coding RNA in hepatocellular
carcinoma-From m(6)A modification to blood biomarkers. Cells.
12(2272)2023.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Zhang K, Barry AE, Lamm R, Patel K,
Schafer M and Dang H: The role of RNA binding proteins in
hepatocellular carcinoma. Adv Drug Deliv Rev.
182(114114)2022.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Xing L, Wang ZK, Li DM, Li J and Liu M:
RNA-based therapies in hepatocellular carcinoma: state of the art
and clinical perspectives. Hepatoma Res. 10(24)2024.
|
|
145
|
Wang Y, Hylemon PB and Zhou H: Long
Noncoding RNA H19: A key player in liver diseases. Hepatology.
74:1652–1659. 2021.PubMed/NCBI View Article : Google Scholar
|
